NI201700128A - Composiciones de acido obeticolico y metodos de uso. - Google Patents

Composiciones de acido obeticolico y metodos de uso.

Info

Publication number
NI201700128A
NI201700128A NI201700128A NI201700128A NI201700128A NI 201700128 A NI201700128 A NI 201700128A NI 201700128 A NI201700128 A NI 201700128A NI 201700128 A NI201700128 A NI 201700128A NI 201700128 A NI201700128 A NI 201700128A
Authority
NI
Nicaragua
Prior art keywords
methods
acid compositions
obeticolic acid
obeticolic
dissolution
Prior art date
Application number
NI201700128A
Other languages
English (en)
Inventor
G Lancaster Richard
K Olmstead Kay
Kagihiro Masashi
Taoka Ikuko
Matono Mitsuhiro
Pruzanski Mark
Shapiro David
Hooshmand-Rad Roya
Pencek Richard
Sciacca Cathi
Eliot Lise
Edwards Jeffrey
A Macconell Leigh
Marmon Tonya
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57198868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201700128(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of NI201700128A publication Critical patent/NI201700128A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La divukgación se refiere a formulaciones de ácido obeticólico con estabilidad, disolución y/o solubilidad mejoradas, a métodos para preparar las mismas para su uso y a métodos para tratar diversas enfermedades y afecciones.
NI201700128A 2015-04-27 2017-10-26 Composiciones de acido obeticolico y metodos de uso. NI201700128A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562153040P 2015-04-27 2015-04-27
US201662317933P 2016-04-04 2016-04-04

Publications (1)

Publication Number Publication Date
NI201700128A true NI201700128A (es) 2018-04-11

Family

ID=57198868

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201700128A NI201700128A (es) 2015-04-27 2017-10-26 Composiciones de acido obeticolico y metodos de uso.

Country Status (25)

Country Link
US (9) US10052337B2 (es)
EP (3) EP4371616A3 (es)
JP (2) JP6941057B2 (es)
KR (1) KR20170140325A (es)
CN (1) CN107531742A (es)
AU (2) AU2016255045B2 (es)
BR (1) BR112017023161A2 (es)
CA (1) CA2983609C (es)
CL (1) CL2017002727A1 (es)
CO (1) CO2017011535A2 (es)
CR (1) CR20170492A (es)
EA (1) EA201792354A1 (es)
EC (1) ECSP17078433A (es)
IL (2) IL294575A (es)
MA (1) MA41999A (es)
MX (1) MX2017013805A (es)
NI (1) NI201700128A (es)
PE (1) PE20180690A1 (es)
PH (1) PH12017501956A1 (es)
SG (2) SG11201708606VA (es)
SV (1) SV2017005555A (es)
TN (1) TN2017000452A1 (es)
TW (1) TWI723017B (es)
WO (1) WO2016176208A1 (es)
ZA (1) ZA201707981B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP3712254A1 (en) 2014-05-28 2020-09-23 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
KR20180125573A (ko) * 2016-03-31 2018-11-23 인터셉트 파마슈티컬즈, 인크. 유효 성분의 화학적 안정성이 뛰어난 필름 코팅정
WO2017180577A1 (en) * 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating cancer
EP4177335A1 (en) 2016-05-05 2023-05-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
MX2018016400A (es) * 2016-06-29 2019-09-02 Menlo Therapeutics Inc Uso de antagonistas de neuroquinina 1 para tratar una variedad de afecciones pruríticas.
SG11201903697WA (en) * 2016-11-04 2019-05-30 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
CN108072729A (zh) * 2016-11-18 2018-05-25 华北制药集团新药研究开发有限责任公司 一种测定奥贝胆酸片溶出度的方法
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
CN108614038B (zh) * 2016-12-13 2022-05-17 亚宝药业集团股份有限公司 一种测定奥贝胆酸原料药有关物质的方法
CN106645497A (zh) * 2017-01-03 2017-05-10 山东省药学科学院 一种奥贝胆酸及其制剂中有关物质的检测方法
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
EP3609997A4 (en) 2017-04-14 2021-03-03 Children's Hospital Medical Center COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
MX2020000873A (es) * 2017-07-24 2020-07-22 Intercept Pharmaceuticals Inc Derivados de ácidos biliares marcados isotópicamente.
US12297457B2 (en) 2017-10-10 2025-05-13 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
WO2019106043A1 (en) * 2017-11-29 2019-06-06 Hexal Ag Pharmaceutical composition comprising obeticholic acid
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
CN108572251B (zh) * 2018-05-31 2020-01-17 中国科学院昆明动物研究所 肝硬化早期小分子标志物及其应用
US12421500B2 (en) 2018-07-26 2025-09-23 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
JP2021535753A (ja) 2018-09-12 2021-12-23 チルドレンズ ホスピタル メディカル センター 造血幹細胞およびその派生体の生成のためのオルガノイド組成物
CA3117966A1 (en) * 2018-11-08 2020-05-14 Intercept Pharmaceuticals, Inc. Methods of using obeticholic acid
CN109432431B (zh) * 2018-12-14 2020-06-30 中国药科大学 一种含有sumo抑制剂的组合物及应用
CN109655571B (zh) * 2019-01-08 2021-07-13 丽珠集团新北江制药股份有限公司 一种奥贝胆酸的高效液相色谱分析方法
CN109620812B (zh) * 2019-01-16 2023-07-21 浙江华海药业股份有限公司 一种奥贝胆酸组合物的制备方法
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
EP3946359A1 (en) * 2019-03-26 2022-02-09 Intercept Pharmaceuticals, Inc. Methods of diagnosis and treatment of liver diseases using obeticholic acid
WO2020198576A1 (en) * 2019-03-28 2020-10-01 The Board Of Trustees Of The University Of Illinois Methods of modulating regulatory t cells
CN114174494A (zh) 2019-05-31 2022-03-11 儿童医院医学中心 产生和扩增造血干细胞的方法
CA3141814A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
EP4041233A1 (en) * 2019-09-30 2022-08-17 Novartis AG Treatment comprising the use of fxr agonists
WO2021176430A1 (ru) * 2020-03-06 2021-09-10 Актив Трєнд Лимитєд Применение группы маркеров для диагностики и коррекции лечения первичного билиарного холангита, фармацевтическая композиция и твердая дозированная форма для лечения первичного билиарного холангита
CN115856110B (zh) * 2020-04-23 2025-03-04 江西科睿药业有限公司 一种3α,7α-二羟基-6α-乙基-5β-胆烷-24-醛的高效液相色谱检测方法
US20230201222A1 (en) * 2020-05-13 2023-06-29 Children's Hospital Medical Center Alleviation of liver injury by activating the signaling pathway mediated by farnesoid x receptor
CN111690731B (zh) * 2020-05-22 2021-09-28 河南大学 Fxr激动剂在治疗肝性脑病中的应用
CN111812264B (zh) * 2020-07-09 2021-06-15 苏州旭辉检测有限公司 一种去氧胆酸类化合物的生物样品分析方法
WO2022051321A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a fxr agonist
WO2022076683A1 (en) * 2020-10-07 2022-04-14 Intercept Pharmaceuticals, Inc. Methods of treating coronaviral infection with obeticholic acid
CN113143950B (zh) * 2021-05-17 2023-04-18 河北医科大学第二医院 一种治疗肝病的药物组合物及其应用
WO2023147141A1 (en) * 2022-01-28 2023-08-03 Intercept Pharmaceuticals, Inc. Combination therapy
WO2023181077A1 (en) * 2022-03-24 2023-09-28 Zenvision Pharma Llp Stable liquid composition comprising obeticholic acid or salts thereof
US12343351B2 (en) 2022-03-25 2025-07-01 Rutgers, The State University Of New Jersey Pulmonary function treatment
IL315941A (en) * 2022-04-21 2024-11-01 Intercept Pharmaceuticals Inc Uses of farnesoid x receptor agonists
WO2024043842A1 (en) * 2022-08-22 2024-02-29 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients
WO2024104960A1 (en) 2022-11-15 2024-05-23 Synthon B.V. Stable formulation comprising obeticholic acid

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
ZA876640B (en) 1986-09-26 1988-03-08 Warner-Lambert Company Treated lipid regulator
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
ATE303399T1 (de) * 2001-03-12 2005-09-15 Intercept Pharmaceuticals Inc Steroide als agonisten für fxr
KR100943309B1 (ko) 2001-06-14 2010-02-23 오츠카 세이야쿠 가부시키가이샤 의약 조성물
US6933380B2 (en) 2001-10-19 2005-08-23 Yung-Zip Chemical Ind. Co., Ltd. Excipients containing low residual solvent and method for producing the same
BR0312426A (pt) 2002-07-03 2005-12-06 Esperion Therapeutics Inc Composição farmacêutica, métodos para tratar, prevenir ou controlar um colesterol, dislipidemia ou distúrbio relacionado, para reduzir ou evitar um efeito adverso associado com monoterapia de pantetina e para reduzir ou evitar um efeito adverso associado com monoterapia de segundo agente ativo, e, kit
US20050101505A1 (en) * 2003-11-06 2005-05-12 Daniel Wood Liquid laundry detergent composition having improved color-care properties
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
WO2007008480A1 (en) 2005-07-07 2007-01-18 Nanotherapeutics, Inc. Process for milling and preparing powders and compositions produced thereby
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
RU2011139643A (ru) * 2009-03-17 2013-04-27 Акскан Фарма, Инк. Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты
NZ595902A (en) 2009-04-24 2014-10-31 Iceutica Pty Ltd Method for the production of commercial nanoparticle and microparticle powders
BR112012026843A2 (pt) 2010-04-20 2016-07-12 Cipla Ltd composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv
PT3336097T (pt) 2012-06-19 2020-10-29 Intercept Pharmaceuticals Inc Preparação da forma não cristalina de ácido obeticólico
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
CA2904129A1 (en) 2013-03-15 2014-09-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CA2912139C (en) 2013-05-14 2021-04-20 Roberto Pellicciari 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
PL3043865T3 (pl) * 2013-09-11 2021-07-05 Institut National De La Santé Et De La Recherche Médicale (Inserm) SPOSOBY I KOMPOZYCjE FARMACEUTYCZNE W LECZENIU ZAKAŻENIA WIRUSEM ZAPALENIA WĄTROBY TYPU B
CN105801653B (zh) 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso

Also Published As

Publication number Publication date
TWI723017B (zh) 2021-04-01
US10052337B2 (en) 2018-08-21
US20200171053A1 (en) 2020-06-04
ZA201707981B (en) 2019-03-27
EP3971199A1 (en) 2022-03-23
EP4371616A2 (en) 2024-05-22
US20170035784A1 (en) 2017-02-09
TW201703773A (zh) 2017-02-01
MA41999A (fr) 2018-03-07
US20200046735A1 (en) 2020-02-13
CN107531742A (zh) 2018-01-02
MX2017013805A (es) 2018-09-06
CO2017011535A2 (es) 2018-01-31
CA2983609A1 (en) 2016-11-03
SG11201708606VA (en) 2017-11-29
BR112017023161A2 (pt) 2018-07-24
JP2021183651A (ja) 2021-12-02
IL294575A (en) 2022-09-01
KR20170140325A (ko) 2017-12-20
AU2020205315A1 (en) 2020-08-06
CA2983609C (en) 2024-05-07
EP4371616A3 (en) 2024-08-28
AU2016255045B2 (en) 2020-04-16
US20260000682A1 (en) 2026-01-01
TN2017000452A1 (en) 2019-04-12
SG10202003110PA (en) 2020-05-28
SV2017005555A (es) 2019-01-18
US20190076446A1 (en) 2019-03-14
US20190255071A1 (en) 2019-08-22
PH12017501956A1 (en) 2018-03-26
US10646499B2 (en) 2020-05-12
US20220133745A1 (en) 2022-05-05
CR20170492A (es) 2018-05-15
EP3288958A1 (en) 2018-03-07
EP3288958A4 (en) 2018-09-26
US20200046736A1 (en) 2020-02-13
EA201792354A1 (ru) 2018-03-30
JP2018514534A (ja) 2018-06-07
IL255269B (en) 2022-08-01
CL2017002727A1 (es) 2018-04-27
PE20180690A1 (es) 2018-04-23
US20200054650A1 (en) 2020-02-20
ECSP17078433A (es) 2018-02-28
JP6941057B2 (ja) 2021-09-29
IL255269A (en) 2018-02-28
WO2016176208A1 (en) 2016-11-03
AU2016255045A1 (en) 2017-11-09
US10751349B2 (en) 2020-08-25
US10758549B2 (en) 2020-09-01

Similar Documents

Publication Publication Date Title
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
CL2020000946A1 (es) Métodos y composiciones para la producción de trifosfato de nucleosido y ácido ribonucleico
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
DOP2017000176A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2018007022A (es) Metodos para tratar la enfermedad de huntington.
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
CO2017002253A2 (es) Compuesto dirigido a il-23a y tnf-alfa
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
UY35796A (es) ?derivados de dihidrohidantoína sustituidos, procesos para prepararlos, composiciones herbicidas y su uso en plantas?.
MX376122B (es) Composiciones de plinabulina.
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
MX384877B (es) Composiciones de éster de colina de ácido lipoico y métodos de uso.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
CL2019002729A1 (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MX382116B (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
CO2019008110A2 (es) Activador de nrf2
CR20150659A (es) Derivados de prodroga de triazolpiridinas sustituidas
UY37444A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso